Genotypic and phenotypic description of late-onset Alzheimer’s disease and early onset familial Alzheimer’s: Review
Main Article Content
Abstract
Dementia is known as the loss of multiple areas of cognitive function with respect to a premorbid condition, involving a significant deterioration in functionality. The most common subtype is Alzheimer’s disease, which is defined as a neurodegenerative disorder that causes a progressive deterioration in memory and other mental capacities due to volume loss in temporal lobes, especially in mesial aspects, such as the hippocampus and the entorhinal cortex. Approximately 5% of patients affected by this disease have a hereditary form, with an early onset (before 65 years) or a late onset (after 65 years). Early onset Alzheimer’s disease has a genetic autosomal dominant inheritance pattern, which can be caused by mutations in the gene encoding for the amyloid precursor protein, presenilin-1, or presenilin-2. In the cases of late onset Alzheimer’s disease, there is a complex genetic influence, with multiple susceptibility factors, where the ApoE4 allele is the main and most recognized factor. Alzheimer’s disease is a heterogeneous dementia, both in genotype and phenotype, varying in intensity and symptoms, age of onset, and severity of the disease, depending on the different mutations that a patient may have and the interactions with environmental factors.
Article Details
References
Alanis-Niño G, Garza-Maroquin J, González-Arellano A. Prevalencia de demencia en pacientes geriátricos. Rev Med Inst Mex Seguro Soc 2008; 46(1):27-32.
Wilkosz PA, Seltman HJ, Devlin B, Weamer EA, Lopez OL, DeKosky ST. Trajectories of cognitive decline in Alzheimer’s disease. Int Psychogeriatr 2010; 22(2):281-290.
Ballard C. Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer’s disease. Lancet 2011; 377(9770):1019-1031.
Wilson RS, Li Y, Aggarwal NT, Barnes LL, McCann JJ, Gilley DW. Education and the course of cognitive decline in Alzheimer disease. Neurology 2004; 63(7):1198-1202.
Querfurth HW, LaFerla FM. Alzheimer’s disease. N Engl J Med 2010; 362(4):329-344.
Shepherd C, McCann H, Halliday GM. Variations in the neuropathology of familial Alzheimer’s disease. Acta Neuropathol 2009; 118(1):37-52.
Manzano-Palomo S, Morena-Vicente MA, Barquero MS. Neurotransmisores en la Enfermedad de Alzheimer. Rev Neurol 2006; 42(6):350-353.
Mann DM, Pickering-Brown SM, Takeuchi A, Iwatsubo T. Amyloid angiopathy and variability in amyloid beta deposition is determined by mutation position in presenilin-1-linked Alzheimer’s disease. Am J Pathol 2001; 158(6):2165-2175.
Carvajal-Castrillón J, Aguirre D, Lopera F. Perfil clínico y cognitivo de la atrofia cortical posterior y sus diferencias con la enfermedad de Alzheimer esporádica tardía y familiar precoz. Acta Neurol Colom 2010; 26(2):75-86.
Arango-Lasprilla JC, Fernández S. La enfermedad de Alzheimer. En R. Alarcón, (Ed.), Las demencias: aspectos clínicos, neuropsicológicos y tratamiento. México: Manual Moderno; 2003.
Lopera F. Plan de estudio del paciente con demencia y diagnóstico diferencial con el Alzheimer. Iatreia 1997; 10:106-113.
Lopera F. Anamnesis en el estudio del paciente con demencia. Rev Neurol 2001; 32(12):1187-1192.
Carvajal-Castrillón J, Gil L, Tirado V, Lopera J, Londoño A, Lopera F. Atrofia cortical posterior: descripción clínica y neuroimágenes de tres casos. Acta Neurol Colomb 2008; 24:74-80.
Lopera F. Enfermedad de Alzheimer familiar. Neuropsicología, Neuropsiquiatría y Neurociencias 2012; 12:163-188.
Martin JJ, Gheuens J, Bruyland M, Cras P, Vandenberghe A, Masters CL, et al. Early-onset Alzheimer’s disease in 2 large Belgian families. Neurology 1991; 41(1):62-68.
Cornejo W, Lopera F, Uribe C, Salinas M. Descripción de una familia con demencia presenil tipo Alzheimer. Acta Médica Colombiana 1987; 12:55-61
Klunemann HH, Rogaeva E, Neumann M, Kretzschmar HA, Kandel M, Toulina A, et al. Novel PS1 mutation in a Bavarian kindred with familial Alzheimer disease. Alzheimer Dis Assoc Disord 2004; 18(4):256-258.
Godbolt AK, Waldman AD, MacManus DG, Schott JM, Frost C, Cipolotti L, et al. MRS shows abnormalities before symptoms in familial Alzheimer disease. Neurology 2006; 66(5):718-722.
Ataka S, Tomiyama T, Takuma H, Yamashita T, Shimada H, Tsutada T, et al. A novel presenilin-1 mutation (Leu85Pro) in early-onset Alzheimer disease with spastic paraparesis. Arch Neurol 2004; 61(11):1773-1776.
O’Riordan S, McMonagle P, Janssen JC, Fox NC, Farrell M, Collinge J, et al. Presenilin-1 mutation (E280G), spastic paraparesis, and cranial MRI white-matter abnormalities. Neurology 2002; 59(7):1108-1110.
Crook R, Verkkoniemi A, Perez-tur J, Mehta N, Baker M, Houlden H, et al. A variant of Alzheimer’s disease with spastic paraparesis and unusual plaques due to deletion of exon 9 of presenilin 1. Nat Med 1998; 4(4):452-455.
Moretti P, Lieberman AP, Wilde EA, Giordani BI, Kluin KJ, Koeppe RA, et al. Novel insertional presenilin 1 mutation causing Alzheimer disease with spastic paraparesis. Neurology 2004; 62(10):1865-1868.
Rudzinski LA, Fletcher RM, Dickson DW, Crook R, Hutton ML, Adamson J, et al. Early onset familial Alzheimer Disease with spastic paraparesis, dysarthria, and seizures and N135S mutation in PSEN1. Alzheimer Dis Assoc Disord 2008; 22(3):299-307.
Ryan NS, Rossor MN. Correlating familial Alzheimer’s disease gene mutations with clinical phenotype. Biomark Med 2010; 4(1):99-112.
Setó-Salvia N, Clarimón J. Genética de la Enfermedad de Alzheimer. Rev Neurol 2010; 50:360-364.
Rademakers R, Cruts M, Van Broeckhoven C. Genetics of early-onset Alzheimer dementia. Sci World J 2003; 3:497-519.
Brouwers N, Sleegers K, Van Broeckhoven C. Molecular genetics of Alzheimer’s disease: an update. Ann Med 2008; 40(8):562-583.
Holmes C. Genotype and phenotype in Alzheimer’s disease. Bri J Psychiatry 2002; 180:131-134.
Haan J, Bakker E, Bornebroek M, Roos RA. From gene to disease: Amyloid-beta precursor protein gene instrumental in hereditary cerebral amyloid angiopathies. Ned Tijdschr Geneeskd 2001; 145(34):1639-1641.
Tirado V, Motta M, Aguirre-Acevedo DC, Pineda DA, Lopera F. Analysis of intrusive errors in a memory test as possible pre-clinical marker of familial Alzheimer disease, in E280A presenilin-1 mutation carrier. Rev Neurol 2008; 47(6):290-294.
Acosta-Baena N, Sepulveda-Falla D, Lopera-Gómez CM, Jaramillo-Elorza MC, Moreno S, Aguirre-Acevedo DC, et al. Pre-dementia clinical stages in presenilin 1 E280A familial earlyonset Alzheimer’s disease: A retrospective cohort study. Lancet Neurol 2011; 10(3):213-220.
Arango-Lasprilla JC, Cuetos F, Uribe C, Valencia C, Lopera F. Cognitive changes in the preclinical phase of familial Alzheimer´s disease. J Clin Exp Neuropsychol 2007; 29(8):892-900.
Ridha BH, Barnes J, Bartlett JW, Godbolt A, Pepple T, Rossor MN, et al. Tracking atrophy progression in familial Alzheimer’s disease: A serial MRI study. Lancet Neurol 2006; 5(10):828-884.
Cuetos F, Arango-Lasprilla JC, Uribe C, Valencia C, Lopera F. Linguistic changes in verbal expression: A preclinical marker of Alzheimer’s disease. J Int Neuropsychol Soc 2007; 13(3):433- 439.
Tirado V, Muñoz C, Aguirre D, Pineda D, Lopera F. Desempeño de portadores y no portadores de la mutación E280A para enfermedad de Alzheimer familiar en una prueba de denominación. Rev Neurol 2004; 39(4):322-326.
Parra MA, Abrahams S, Logie RH, Della SS. Visual short-term memory binding in Alzheimer’s disease and depression. J Neurol 2010; 257(7):1160-1169.
Petersen RC. Mild cognitive Impairment as a clinical entity and treatment target. Arch Neurol 2005; 62(7):1160-1163.
Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol 1999; 56(3):303-308.
Olazarán-Rodríguez J, Agüera-Ortiz LF, Muñiz-Schwochert R. Síntomas psicológicos y conductuales de la demencia: prevención, diagnóstico y tratamiento. Rev Neurol 2012; 55(10):598-608.
Robles-Bayón A. Acción de la memantina sobre la alteración cognitiva del paciente con demencia: reflexiones tras dos años de experiencia en España. Rev Neurol 2006; 42(5):288-296.
Velilla-Jiménez LM, Soto-Ramírez E, Pineda D. Efectos de un programa de estimulación cognitiva en la memoria operativa de pacientes con deterioro cognitivo leve amnésico. Rev Chil Neuropsicol 2010; 5(3):185-198.
